GeoVax develops vaccines and immunotherapies using a modified vaccinia ankara virus-like particle vaccine platform. Development programs focus on vaccines against COVID-19, hemorrhagic fever viruses, malaria, zika, and HIV, as well as immunotherapy programs targeting tumor-associated antigen MUC1 and HPV-induced cancers. As a pre-commercial clinical-stage company, GeoVax relies on government contracts and institutional partnerships rather than traditional commercial revenue streams.
Cyborg Score Rationale
GeoVax had approximately $5 million in cash at the end of Q3 2025 with high cash burn rates from R&D, increasing the likelihood of future stock offerings and significant dilution. The company is pre-revenue with no approved products, relying entirely on grant funding and equity offerings to fund operations. Stock performance has been severely negative, with warrants trading at negligible levels.
Top Insights
GEO-CM04S1 is being advanced in Phase 2 trials across three patient populations: primary vaccine for immunocompromised patients, booster for chronic lymphocytic leukemia patients, and booster for healthy adults previously vaccinated with mRNA vaccines.
Primary funding sources come from governmental agencies and academic/research institutions through collaboration agreements rather than traditional commercial customers.
In July 2025, GeoVax initiated a research program to evaluate needle-free, self-administered GEO-MVA vaccine delivery via Vaxxas' microarray patch technology for pandemic preparedness.
In September 2025, GeoVax completed a $2.5 million registered direct offering to institutional investors at $0.63 per share with accompanying warrants.
Named Competitors
Next-generation COVID-19 vaccines — mRNA-based vaccines and therapeutics
Viral vector vaccines — DNA-based vaccine and immunotherapy platform
Clinical-stage vaccine development — AI-driven therapeutic vaccine development
Therapeutic vaccine platforms — Plant-derived vaccine and therapeutic protein production
Recent Developments
(September 2025) Completed $2.5 million registered direct offering to healthcare-focused institutional investors
(July 2025) Initiated research program with Vaxxas for needle-free microarray patch delivery of GEO-MVA vaccines
(Q3 2025) Cash balance of approximately $5 million with elevated burn rates creating capital pressure
Open the full interactive GeoVax Labs, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.